Japan becomes first country to approve Ronapreve COVID-19 treatment

Agence France-Presse

<p>GENEVA - Swiss pharmaceutical giant Roche said Tuesday that Japan had become the first country to fully approve its Ronapreve antibody treatment for patients with mild to moderate COVID-19.</p><p>The approval was based on phase 3 trials finding that the antibody cocktail dramatically reduced the likelihood that mild or moderate COVID-19 patients would develop into serious illness causing hospitalization or death.</p><p>Ronapreve, developed in cooperation with US biotech firm Regeneron, was approved by Japan&#x27;s ministry of health, labor and welfare, Roche said in a statement, confirming it was the &quot;first country&quot; to do so.</p><p>&quot;Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death,&quot; Roche chief medical officer and product development chief Levi Garraway said in a statement.</p><p>&quot;Its ability to retain activity against emerging variants, including the Delta variant, has been demonstrated in preclinical studies,&quot; he said.</p><p>Roche said the phase 3 trials of Ronapreve had shown that high-risk non-hospitalized patients treated with the drug had a 70 percent reduction in subsequent hospitalization and death.</p><p>It also shorted the period of symptomatic illness by four days, Roche said, adding that the phase 1 trials had showed the safety and tolerability of the drug among the Japanese population.</p><p>Outside Japan, the antibody combination has been authorized for emergency or temporary pandemic use in a number of countries and regions, including the European Union, United States, India, Switzerland and Canada, Roche said.</p><p>The blend is currently undergoing a rolling review by the European Medicines Agency, which has granted its use as a treatment option for COVID-19 patients who do not require oxygen, but who are at high risk of developing severe disease.</p><ul class="op-related-articles">	<li><a href="https://news.abs-cbn.com/spotlight/03/25/21/doh-says-experimental-drugs-used-for-covid-19-running-low">DOH says experimental drugs used for COVID-19 running low</a></li>	<li><a href="https://news.abs-cbn.com/news/05/07/21/who-state-regulators-asked-to-consider-positive-results-of-ivermectin-trials-on-covid-19">WHO, state regulators asked to consider positive results of ivermectin trials on COVID-19</a></li>	<li><a href="https://news.abs-cbn.com/overseas/06/15/21/astrazeneca-hits-snag-in-covid-19-drug-development">AstraZeneca hits snag in COVID-19 drug development</a></li></ul><div><strong>nl/jv</strong></div><div><strong>© Agence France-Presse</strong></div><div><strong> RELATED VIDEO</strong></div><figure class="op-interactive"><iframe allow="autoplay; fullscreen" frameBorder="0" height="100%" id="ivsplayer01" scrolling="no" src="https://player.ivideosmart.com/ivsplayer/v4/dist/html/iframe-src.html?iframeid=ivsplayer01&amp;key=e8c22c015ca9eafa76f1e3edfa03c603&amp;spid=3001339&amp;vid=1730952" width="100%"></iframe></figure><div class="iwantbar">Watch more in <a href="//www.iwantv.com.ph/">iWantv</a> or <a href="//tfc.tv/">TFC.tv</a></div>

<p>Swiss pharmaceutical giant Roche said Tuesday that Japan had become the first country to fully approve its Ronapreve antibody treatment for patients with mild to moderate COVID-19.</p>

Swiss pharmaceutical giant Roche said Tuesday that Japan had become the first country to fully approve its Ronapreve antibody treatment for patients with mild to moderate COVID-19.

Japan becomes first country to approve Ronapreve COVID-19 treatment | ABS-CBN

Halalan 2025

Entertainment

News

Metro.Style

Lifestyle

Sports

More

Traffic

Horoscope

Overseas

Japan becomes first country to approve Ronapreve COVID-19 treatment

Japan becomes first country to approve Ronapreve COVID-19 treatment

Agence France-Presse

Published Jul 20, 2021 07:00 PM PHT

Read More:

ANC

COVID-19

COVID-19 treatment

Ronapreve

Japan

Roche

Regeneron

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.